ZA202107499B - Compounds, compositions and methods - Google Patents

Compounds, compositions and methods

Info

Publication number
ZA202107499B
ZA202107499B ZA2021/07499A ZA202107499A ZA202107499B ZA 202107499 B ZA202107499 B ZA 202107499B ZA 2021/07499 A ZA2021/07499 A ZA 2021/07499A ZA 202107499 A ZA202107499 A ZA 202107499A ZA 202107499 B ZA202107499 B ZA 202107499B
Authority
ZA
South Africa
Prior art keywords
compositions
compounds
methods
Prior art date
Application number
ZA2021/07499A
Other languages
English (en)
Inventor
Vicente Fidalgo Javier De
Anthony A Estrada
Jianwen A Feng
Zachary K Sweeney
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of ZA202107499B publication Critical patent/ZA202107499B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2021/07499A 2019-04-11 2021-10-05 Compounds, compositions and methods ZA202107499B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832775P 2019-04-11 2019-04-11
PCT/US2020/027742 WO2020210684A1 (en) 2019-04-11 2020-04-10 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
ZA202107499B true ZA202107499B (en) 2022-06-29

Family

ID=72752101

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/07499A ZA202107499B (en) 2019-04-11 2021-10-05 Compounds, compositions and methods

Country Status (19)

Country Link
US (1) US12358896B2 (cg-RX-API-DMAC7.html)
EP (1) EP3953348B1 (cg-RX-API-DMAC7.html)
JP (1) JP7623294B2 (cg-RX-API-DMAC7.html)
KR (1) KR102962366B1 (cg-RX-API-DMAC7.html)
CN (1) CN113939294A (cg-RX-API-DMAC7.html)
AR (1) AR118641A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020272045B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020027A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136447A1 (cg-RX-API-DMAC7.html)
DK (1) DK3953348T3 (cg-RX-API-DMAC7.html)
EA (1) EA202192530A1 (cg-RX-API-DMAC7.html)
ES (1) ES3018383T3 (cg-RX-API-DMAC7.html)
IL (1) IL287120B2 (cg-RX-API-DMAC7.html)
MA (1) MA55624A (cg-RX-API-DMAC7.html)
MX (1) MX2021012392A (cg-RX-API-DMAC7.html)
SG (1) SG11202111058XA (cg-RX-API-DMAC7.html)
TW (1) TWI851710B (cg-RX-API-DMAC7.html)
WO (1) WO2020210684A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107499B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086182A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
AU2021371697B2 (en) * 2020-10-29 2024-10-24 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
CN116120291B (zh) * 2023-04-11 2023-06-30 英矽智能科技(上海)有限公司 吲唑类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
PT3472153T (pt) * 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
WO2018217946A1 (en) * 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods
CA3086182A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds

Also Published As

Publication number Publication date
ES3018383T3 (es) 2025-05-16
EP3953348B1 (en) 2024-12-18
CN113939294A (zh) 2022-01-14
AU2020272045A1 (en) 2021-10-28
IL287120B1 (en) 2025-02-01
BR112021020027A2 (pt) 2021-12-07
TWI851710B (zh) 2024-08-11
JP7623294B2 (ja) 2025-01-28
DK3953348T3 (da) 2025-03-17
WO2020210684A1 (en) 2020-10-15
JP2022526015A (ja) 2022-05-20
AR118641A1 (es) 2021-10-20
KR102962366B1 (ko) 2026-05-11
TW202104213A (zh) 2021-02-01
AU2020272045B2 (en) 2026-01-15
EP3953348A1 (en) 2022-02-16
MX2021012392A (es) 2021-11-12
CA3136447A1 (en) 2020-10-15
EA202192530A1 (ru) 2022-03-15
IL287120B2 (en) 2025-06-01
US20220220094A1 (en) 2022-07-14
EP3953348A4 (en) 2023-01-18
SG11202111058XA (en) 2021-11-29
IL287120A (en) 2021-12-01
KR20210151887A (ko) 2021-12-14
US12358896B2 (en) 2025-07-15
MA55624A (fr) 2022-02-16

Similar Documents

Publication Publication Date Title
IL285302A (en) Compounds, preparations and methods
SG11202108367XA (en) Immunomodulators, compositions and methods thereof
SG11202000532SA (en) Compounds, compositions and methods
HUE062446T2 (hu) Vegyületek, készítmények és eljárások
GB201903287D0 (en) Composition
IL284800A (en) Methods, uses and compositions
GB202017595D0 (en) Compositions, and methods and uses relating thereto
GB201912061D0 (en) Composition
GB2576614B (en) Compositions, uses and methods
IL270505B1 (en) Compounds, preparations and methods
GB201811100D0 (en) Composition
SG11202006994XA (en) Antibacterial compounds, compositions thereof, and methods using same
GB201913593D0 (en) Composition
IL287120A (en) Compounds, preparations and methods
GB201916374D0 (en) Composition
GB201804163D0 (en) Uses, compositions and methods
GB201907225D0 (en) Composition
GB201916058D0 (en) Composition
GB201911694D0 (en) Composition
GB201911454D0 (en) Composition
GB2581369B (en) Composition
GB201918997D0 (en) Composition
GB201916352D0 (en) Composition
GB201916221D0 (en) Composition
GB201916217D0 (en) Composition